Abstract Number: 2633 • 2015 ACR/ARHP Annual Meeting
Association of Medication Beliefs, Self-Efficacy, and Adherence in a Diverse Cohort of Adults with Rheumatoid Arthritis
Background/Purpose: Adherence to disease-modifying anti-rheumatic drugs (DMARDs) among rheumatoid arthritis (RA) patients ranges from 30% to 107%, leading to potential adverse outcomes. Patient beliefs about…Abstract Number: 1050 • 2015 ACR/ARHP Annual Meeting
Response to Baricitinib at 4 Weeks Predicts Response at 12 and 24 Weeks in Patients with Rheumatoid Arthritis: Results from Two Phase 3 Studies
Background/Purpose: Baricitinib (bari), an oral, reversible inhibitor of Janus kinase (JAK)1/JAK2, improved signs and symptoms in phase 3, placebo (PBO)-controlled studies in patients (pts) with…Abstract Number: 2656 • 2015 ACR/ARHP Annual Meeting
Analysis of Morning Stiffness Response in Rheumatoid Arthritis Patients with Low Disease Activity Receiving Delayed-Release Prednisone Plus Dmards As Compared to Placebo Plus Dmards
Background/Purpose: Patient reported outcomes such as morning stiffness are reported frequently in rheumatoid arthritis (RA) patients. But little has been reported about the presence and…Abstract Number: 1205 • 2015 ACR/ARHP Annual Meeting
The Spectrum of Early RA Practice Across the Globe: Results from a Multinational Cross Sectional Survey
Background/Purpose: Early diagnosis & treatment are crucial to the management of rheumatoid arthritis (RA). Despite this, the approach to early RA management appears to be…Abstract Number: 2669 • 2015 ACR/ARHP Annual Meeting
Persistency of Patient Reported Morning (AM) Stiffness in a Large US Registry Cohort of Rheumatoid Arthritis (RA) Patients Initiating New DMARD Therapy
Background/Purpose: AM stiffness is a common yet under-appreciated symptom in RA. The longitudinal impact of AM stiffness has not been previously investigated. This study evaluated…Abstract Number: 427 • 2015 ACR/ARHP Annual Meeting
The Impact of Biologic Agent Initiation after 1 Versus 2 Prior Csdmards in Patients with Rheumatoid Arthritis
Background/Purpose: Patients with Rheumatoid Arthritis (RA) who don’t respond to conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) should be treated with biologic agents(1). The objective…Abstract Number: 1488 • 2015 ACR/ARHP Annual Meeting
Following the American College of Rheumatology Quality Guidelines Can Enhance the Safety of Rheumatoid Arthritis Patients Treated with Disease Modifying Drugs
Background/Purpose: Adverse events (AEs) and serious adverse events (SAEs) from disease modifying drugs (DMARDs) for Rheumatoid Arthritis (RA) can result in significant morbidity and even…Abstract Number: 2729 • 2015 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcome of Iguratimod for Rheumatoid Arthritis
Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…Abstract Number: 498 • 2015 ACR/ARHP Annual Meeting
Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), the non-adherence to therapy may impair the clinical outcomes, being often associated with the disease flare and…Abstract Number: 1491 • 2015 ACR/ARHP Annual Meeting
Effects of Drug Induced Toxicity on Patient Reported Outcomes in Early Rheumatoid Arthritis Treated-to-Target Using Conventional Triple DMARD Therapy
Background/Purpose: While the introduction of the treat-to-target (T2T) strategy is associated with lower disease activity scores in rheumatoid arthritis (RA), the potential for increased toxicity…Abstract Number: 2731 • 2015 ACR/ARHP Annual Meeting
Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry
Background/Purpose: For patients with rheumatoid arthritis (RA), there are limited real-world data on factors that predict persistency on biologic therapy or whether use of biologics…Abstract Number: 516 • 2015 ACR/ARHP Annual Meeting
Immunological and Ultrasound Characteristics of Patients with Rheumatoid Arthritis in Clinical Remission – Can We Use These to Predict Outcomes?
Background/Purpose: Remission is the key treatment goal in rheumatoid arthritis (RA). Although clinical remission is increasingly achieved, many patients progress both structurally and functionally. We…Abstract Number: 1553 • 2015 ACR/ARHP Annual Meeting
Effect of Drug Therapy on Net Cholesterol Efflux Capacity of HDL-Enriched Serum in Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased coronary heart disease risk. Some RA therapies may modify this risk, but underlying mechanisms are unclear. The…Abstract Number: 2742 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib Monotherapy Versus Combination Therapy in a Latin American Subpopulation of Patients with Rheumatoid Arthritis: A Pooled Phase 3 Analysis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post-hoc pooled analysis was designed to assess the efficacy and safety…Abstract Number: 546 • 2015 ACR/ARHP Annual Meeting
Adipokines and Insulin-like Growth Factor 1 As Predictors of Clinical and Radiographic Outcomes in Early Rheumatoid Arthritis
Background/Purpose: Adipokines are cytokines/hormones primarily synthesized in white adipose tissue. In rheumatoid arthritis (RA), some adipokines have been associated with worse outcomes (1-3). The aim…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 24
- Next Page »